Loading…

Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals

Synthesis and inhibitory potencies of three types of protease inhibitors of the hepatitis C virus (HCV) full-length NS3 (protease-helicase/NTPase) are reported: (i) inhibitors comprising electrophilic serine traps (pentafluoroethyl ketones, α-keto acids, and α-ketotetrazoles), (ii) product-based inh...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2003-06, Vol.11 (12), p.2551-2568
Main Authors: Johansson, Anja, Poliakov, Anton, Åkerblom, Eva, Wiklund, Karin, Lindeberg, Gunnar, Winiwarter, Susanne, Danielson, U.Helena, Samuelsson, Bertil, Hallberg, Anders
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63
cites cdi_FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63
container_end_page 2568
container_issue 12
container_start_page 2551
container_title Bioorganic & medicinal chemistry
container_volume 11
creator Johansson, Anja
Poliakov, Anton
Åkerblom, Eva
Wiklund, Karin
Lindeberg, Gunnar
Winiwarter, Susanne
Danielson, U.Helena
Samuelsson, Bertil
Hallberg, Anders
description Synthesis and inhibitory potencies of three types of protease inhibitors of the hepatitis C virus (HCV) full-length NS3 (protease-helicase/NTPase) are reported: (i) inhibitors comprising electrophilic serine traps (pentafluoroethyl ketones, α-keto acids, and α-ketotetrazoles), (ii) product-based inhibitors comprising a C-terminal carboxylate group, and (iii) previously unexplored inhibitors comprising C-terminal carboxylic acid bioisosteres (tetrazoles and acyl sulfonamides). Bioisosteric replacement with the tetrazole group provided inhibitors equally potent to the corresponding carboxylates, and substitution with the phenyl acyl sulfonamide group yielded more potent inhibitors. The hexapeptide inhibitors Suc-Asp- d-Glu-Leu-Ile-Cha-Nva-NHSO 2Ph and Suc-Asp- d-Glu-Leu-Ile-Cha-ACPC-NHSO 2Ph with K i values of 13.6 and 3.8 nM, respectively, were approximately 20 times more potent than the corresponding inhibitors with a C-terminal carboxylate and were comparable to the carboxylate-based inhibitor containing the native cysteine, Suc-Asp- d-Glu-Leu-Ile-Cha-Cys-OH ( K i=28 nM). The acyl sulfonamide group constitutes a very promising C-terminal functionality that allows for prime site optimization. Graphic
doi_str_mv 10.1016/S0968-0896(03)00179-2
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_uu_66026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089603001792</els_id><sourcerecordid>73285809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EokPhJ4C8AbVCoX4ktsMGjYZHkUalUgtby3FuOkZ51Xammp_Tf4rTGbVLNj5efOfcq3sQekvJJ0qoOLsipVAZUaU4IfyUECrLjD1DC5qLPOO8pM_R4hE5Qq9C-EsIYXlJX6IjymQhJeMLdL-0uxaHqW2G3nSuhoBNwOMQoY949ElNAOz6jatcHHzAQ4PjBvAGRhNddAGv8Nb5KeBmattsDf1N3OCLK45PLg_u7BxaZ9Pn7OL6MsnpZ7zEduhG41PEFnCIU72bg2vXNODnyassgu9cb9rwGr1oksCbgx6j39-_Xa_Os_WvHz9Xy3Vm85LHDIQyrCgrVuXMUmUll6ZWgvJGMRDpyVktVGVqShNmE17wnLGykLmojBH8GH3c54Y7GKdKj951xu_0YJz-6v4s9eBv9DRpIQib6Q97Ot3odoIQdeeChbY1PQxT0JIzVShSJrDYg9YPIXhoHoMp0XOT-qFJPdekCdcPTWqWfO8OA6aqg_rJdaguAe8PgAnWtI03vXXhicul4kzKxH3Zc5COt3XgdbAOegu182Cjrgf3n1X-AQL3vEI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73285809</pqid></control><display><type>article</type><title>Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals</title><source>Elsevier</source><creator>Johansson, Anja ; Poliakov, Anton ; Åkerblom, Eva ; Wiklund, Karin ; Lindeberg, Gunnar ; Winiwarter, Susanne ; Danielson, U.Helena ; Samuelsson, Bertil ; Hallberg, Anders</creator><creatorcontrib>Johansson, Anja ; Poliakov, Anton ; Åkerblom, Eva ; Wiklund, Karin ; Lindeberg, Gunnar ; Winiwarter, Susanne ; Danielson, U.Helena ; Samuelsson, Bertil ; Hallberg, Anders</creatorcontrib><description>Synthesis and inhibitory potencies of three types of protease inhibitors of the hepatitis C virus (HCV) full-length NS3 (protease-helicase/NTPase) are reported: (i) inhibitors comprising electrophilic serine traps (pentafluoroethyl ketones, α-keto acids, and α-ketotetrazoles), (ii) product-based inhibitors comprising a C-terminal carboxylate group, and (iii) previously unexplored inhibitors comprising C-terminal carboxylic acid bioisosteres (tetrazoles and acyl sulfonamides). Bioisosteric replacement with the tetrazole group provided inhibitors equally potent to the corresponding carboxylates, and substitution with the phenyl acyl sulfonamide group yielded more potent inhibitors. The hexapeptide inhibitors Suc-Asp- d-Glu-Leu-Ile-Cha-Nva-NHSO 2Ph and Suc-Asp- d-Glu-Leu-Ile-Cha-ACPC-NHSO 2Ph with K i values of 13.6 and 3.8 nM, respectively, were approximately 20 times more potent than the corresponding inhibitors with a C-terminal carboxylate and were comparable to the carboxylate-based inhibitor containing the native cysteine, Suc-Asp- d-Glu-Leu-Ile-Cha-Cys-OH ( K i=28 nM). The acyl sulfonamide group constitutes a very promising C-terminal functionality that allows for prime site optimization. Graphic</description><identifier>ISSN: 0968-0896</identifier><identifier>ISSN: 1464-3391</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(03)00179-2</identifier><identifier>PMID: 12757723</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Acylation ; Adenosine Triphosphatases - antagonists &amp; inhibitors ; Amino Acid Sequence ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Binding Sites ; Biological and medical sciences ; FARMACI ; Hepacivirus - drug effects ; Hepacivirus - enzymology ; Kinetics ; Medical sciences ; Models, Molecular ; NATURAL SCIENCES ; NATURVETENSKAP ; Oligopeptides - chemistry ; Oligopeptides - pharmacology ; Pharmacology. Drug treatments ; PHARMACY ; Protease Inhibitors - chemistry ; Protease Inhibitors - pharmacology ; Protein Binding ; RNA Helicases - antagonists &amp; inhibitors ; Serine Endopeptidases - metabolism ; Structure-Activity Relationship ; Sulfonamides - chemistry ; Sulfonamides - pharmacology ; Viral Nonstructural Proteins - antagonists &amp; inhibitors</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2003-06, Vol.11 (12), p.2551-2568</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63</citedby><cites>FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14783277$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12757723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-66026$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Johansson, Anja</creatorcontrib><creatorcontrib>Poliakov, Anton</creatorcontrib><creatorcontrib>Åkerblom, Eva</creatorcontrib><creatorcontrib>Wiklund, Karin</creatorcontrib><creatorcontrib>Lindeberg, Gunnar</creatorcontrib><creatorcontrib>Winiwarter, Susanne</creatorcontrib><creatorcontrib>Danielson, U.Helena</creatorcontrib><creatorcontrib>Samuelsson, Bertil</creatorcontrib><creatorcontrib>Hallberg, Anders</creatorcontrib><title>Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>Synthesis and inhibitory potencies of three types of protease inhibitors of the hepatitis C virus (HCV) full-length NS3 (protease-helicase/NTPase) are reported: (i) inhibitors comprising electrophilic serine traps (pentafluoroethyl ketones, α-keto acids, and α-ketotetrazoles), (ii) product-based inhibitors comprising a C-terminal carboxylate group, and (iii) previously unexplored inhibitors comprising C-terminal carboxylic acid bioisosteres (tetrazoles and acyl sulfonamides). Bioisosteric replacement with the tetrazole group provided inhibitors equally potent to the corresponding carboxylates, and substitution with the phenyl acyl sulfonamide group yielded more potent inhibitors. The hexapeptide inhibitors Suc-Asp- d-Glu-Leu-Ile-Cha-Nva-NHSO 2Ph and Suc-Asp- d-Glu-Leu-Ile-Cha-ACPC-NHSO 2Ph with K i values of 13.6 and 3.8 nM, respectively, were approximately 20 times more potent than the corresponding inhibitors with a C-terminal carboxylate and were comparable to the carboxylate-based inhibitor containing the native cysteine, Suc-Asp- d-Glu-Leu-Ile-Cha-Cys-OH ( K i=28 nM). The acyl sulfonamide group constitutes a very promising C-terminal functionality that allows for prime site optimization. Graphic</description><subject>Acylation</subject><subject>Adenosine Triphosphatases - antagonists &amp; inhibitors</subject><subject>Amino Acid Sequence</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>FARMACI</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - enzymology</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>NATURAL SCIENCES</subject><subject>NATURVETENSKAP</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>PHARMACY</subject><subject>Protease Inhibitors - chemistry</subject><subject>Protease Inhibitors - pharmacology</subject><subject>Protein Binding</subject><subject>RNA Helicases - antagonists &amp; inhibitors</subject><subject>Serine Endopeptidases - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Sulfonamides - chemistry</subject><subject>Sulfonamides - pharmacology</subject><subject>Viral Nonstructural Proteins - antagonists &amp; inhibitors</subject><issn>0968-0896</issn><issn>1464-3391</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1DAUhS0EokPhJ4C8AbVCoX4ktsMGjYZHkUalUgtby3FuOkZ51Xammp_Tf4rTGbVLNj5efOfcq3sQekvJJ0qoOLsipVAZUaU4IfyUECrLjD1DC5qLPOO8pM_R4hE5Qq9C-EsIYXlJX6IjymQhJeMLdL-0uxaHqW2G3nSuhoBNwOMQoY949ElNAOz6jatcHHzAQ4PjBvAGRhNddAGv8Nb5KeBmattsDf1N3OCLK45PLg_u7BxaZ9Pn7OL6MsnpZ7zEduhG41PEFnCIU72bg2vXNODnyassgu9cb9rwGr1oksCbgx6j39-_Xa_Os_WvHz9Xy3Vm85LHDIQyrCgrVuXMUmUll6ZWgvJGMRDpyVktVGVqShNmE17wnLGykLmojBH8GH3c54Y7GKdKj951xu_0YJz-6v4s9eBv9DRpIQib6Q97Ot3odoIQdeeChbY1PQxT0JIzVShSJrDYg9YPIXhoHoMp0XOT-qFJPdekCdcPTWqWfO8OA6aqg_rJdaguAe8PgAnWtI03vXXhicul4kzKxH3Zc5COt3XgdbAOegu182Cjrgf3n1X-AQL3vEI</recordid><startdate>20030612</startdate><enddate>20030612</enddate><creator>Johansson, Anja</creator><creator>Poliakov, Anton</creator><creator>Åkerblom, Eva</creator><creator>Wiklund, Karin</creator><creator>Lindeberg, Gunnar</creator><creator>Winiwarter, Susanne</creator><creator>Danielson, U.Helena</creator><creator>Samuelsson, Bertil</creator><creator>Hallberg, Anders</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope></search><sort><creationdate>20030612</creationdate><title>Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals</title><author>Johansson, Anja ; Poliakov, Anton ; Åkerblom, Eva ; Wiklund, Karin ; Lindeberg, Gunnar ; Winiwarter, Susanne ; Danielson, U.Helena ; Samuelsson, Bertil ; Hallberg, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acylation</topic><topic>Adenosine Triphosphatases - antagonists &amp; inhibitors</topic><topic>Amino Acid Sequence</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>FARMACI</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - enzymology</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>NATURAL SCIENCES</topic><topic>NATURVETENSKAP</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>PHARMACY</topic><topic>Protease Inhibitors - chemistry</topic><topic>Protease Inhibitors - pharmacology</topic><topic>Protein Binding</topic><topic>RNA Helicases - antagonists &amp; inhibitors</topic><topic>Serine Endopeptidases - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Sulfonamides - chemistry</topic><topic>Sulfonamides - pharmacology</topic><topic>Viral Nonstructural Proteins - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johansson, Anja</creatorcontrib><creatorcontrib>Poliakov, Anton</creatorcontrib><creatorcontrib>Åkerblom, Eva</creatorcontrib><creatorcontrib>Wiklund, Karin</creatorcontrib><creatorcontrib>Lindeberg, Gunnar</creatorcontrib><creatorcontrib>Winiwarter, Susanne</creatorcontrib><creatorcontrib>Danielson, U.Helena</creatorcontrib><creatorcontrib>Samuelsson, Bertil</creatorcontrib><creatorcontrib>Hallberg, Anders</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johansson, Anja</au><au>Poliakov, Anton</au><au>Åkerblom, Eva</au><au>Wiklund, Karin</au><au>Lindeberg, Gunnar</au><au>Winiwarter, Susanne</au><au>Danielson, U.Helena</au><au>Samuelsson, Bertil</au><au>Hallberg, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2003-06-12</date><risdate>2003</risdate><volume>11</volume><issue>12</issue><spage>2551</spage><epage>2568</epage><pages>2551-2568</pages><issn>0968-0896</issn><issn>1464-3391</issn><eissn>1464-3391</eissn><abstract>Synthesis and inhibitory potencies of three types of protease inhibitors of the hepatitis C virus (HCV) full-length NS3 (protease-helicase/NTPase) are reported: (i) inhibitors comprising electrophilic serine traps (pentafluoroethyl ketones, α-keto acids, and α-ketotetrazoles), (ii) product-based inhibitors comprising a C-terminal carboxylate group, and (iii) previously unexplored inhibitors comprising C-terminal carboxylic acid bioisosteres (tetrazoles and acyl sulfonamides). Bioisosteric replacement with the tetrazole group provided inhibitors equally potent to the corresponding carboxylates, and substitution with the phenyl acyl sulfonamide group yielded more potent inhibitors. The hexapeptide inhibitors Suc-Asp- d-Glu-Leu-Ile-Cha-Nva-NHSO 2Ph and Suc-Asp- d-Glu-Leu-Ile-Cha-ACPC-NHSO 2Ph with K i values of 13.6 and 3.8 nM, respectively, were approximately 20 times more potent than the corresponding inhibitors with a C-terminal carboxylate and were comparable to the carboxylate-based inhibitor containing the native cysteine, Suc-Asp- d-Glu-Leu-Ile-Cha-Cys-OH ( K i=28 nM). The acyl sulfonamide group constitutes a very promising C-terminal functionality that allows for prime site optimization. Graphic</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12757723</pmid><doi>10.1016/S0968-0896(03)00179-2</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2003-06, Vol.11 (12), p.2551-2568
issn 0968-0896
1464-3391
1464-3391
language eng
recordid cdi_swepub_primary_oai_DiVA_org_uu_66026
source Elsevier
subjects Acylation
Adenosine Triphosphatases - antagonists & inhibitors
Amino Acid Sequence
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Binding Sites
Biological and medical sciences
FARMACI
Hepacivirus - drug effects
Hepacivirus - enzymology
Kinetics
Medical sciences
Models, Molecular
NATURAL SCIENCES
NATURVETENSKAP
Oligopeptides - chemistry
Oligopeptides - pharmacology
Pharmacology. Drug treatments
PHARMACY
Protease Inhibitors - chemistry
Protease Inhibitors - pharmacology
Protein Binding
RNA Helicases - antagonists & inhibitors
Serine Endopeptidases - metabolism
Structure-Activity Relationship
Sulfonamides - chemistry
Sulfonamides - pharmacology
Viral Nonstructural Proteins - antagonists & inhibitors
title Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A33%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acyl%20sulfonamides%20as%20potent%20protease%20inhibitors%20of%20the%20hepatitis%20C%20virus%20full-Length%20NS3%20(Protease-Helicase/NTPase):%20A%20comparative%20study%20of%20different%20C-terminals&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Johansson,%20Anja&rft.date=2003-06-12&rft.volume=11&rft.issue=12&rft.spage=2551&rft.epage=2568&rft.pages=2551-2568&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(03)00179-2&rft_dat=%3Cproquest_swepu%3E73285809%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-e68a259b2b42c18c737ad8613f82e6f8242d68bad11259ce685342295746baa63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73285809&rft_id=info:pmid/12757723&rfr_iscdi=true